Overview

* Abeona Q3 net income and EPS beat analyst expectations

* Company's cash position at $207.5 mln, sufficient for over two years of operations

Outlook

* Company anticipates ZEVASKYN patient treatments to start in 4Q 2025

* Abeona sees strong patient demand and expanding treatment site network

Result Drivers

* PATIENT DEMAND - Abeona reports strong and growing patient demand for ZEVASKYN despite treatment delay

* TREATMENT CENTER EXPANSION - Strategic expansion of QTC network with three activated centers and more onboarding

* MARKET ACCESS - Broad market access with commercial payer coverage and CMS J-code for ZEVASKYN

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Beat -$0.10 -$0.29

(7

Analysts

)

Q3 Net Beat -$5.16 -$16.90

Income mln mln (7

Analysts

)

Q3 Miss -$24.02 -$18.20

Income mln mln (7

From Analysts

Operatio )

ns

Q3 Cash $207.50

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Abeona Therapeutics Inc ( ABEO ) is $20.00, about 79.1% above its November 11 closing price of $4.17

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)